Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches

Tempus AI TEM continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay to detect molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors. It is currently available for research use only, with clinical availability expected later this year. In May, TEM launched its Fuses program to generate valuable insights for both patient care and research. Fuses will accelerate the company’s comprehensive testing portfolio, expanding its suite of AI-enabled diagnostics. In April, Tempus AI announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is its proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR screens, all leveraging AI to rapidly uncover insights for preclinical therapeutic development.In January, Tempus AI launched olivia, an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights. The company also launched an FDA-approved, next-generation sequencing (NGS)-based in vitro diagnostic device, xT CDx. xT CDx is a 648-gene NGS test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.In terms of product in the pipeline, Tempus AI is developing its first whole-genome sequencing test, xH. This test marks the company’s first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with the detection of all clinically relevant variants and advancing the landscape of personalized therapy, specifically in hematological oncology.Tempus AI’s Peers Making Significant Strides With Product InnovationVeracyte VCYT significantly advanced its product pipeline, positioning itself as a strong player in the precision diagnostics and AI-driven testing space. The company launched its Decipher Prostate metastatic test in a limited capacity in April, with a full rollout planned for June. This launch expands Decipher’s reach to the entire spectrum of prostate cancer, providing actionable insights for metastatic patients to guide treatment decisions and avoid unnecessary chemotherapy. Additionally, Veracyte plans to launch an updated version of its Afirma test in summer 2025, incorporating its v2 transcriptome. It also aims to launch the Prosigna lab-developed test for breast cancer in the United States in 2026. Finally, Veracyte is progressing toward the launch of its Percepta Nasal Swab test for lung cancer risk assessment.Myriad Genetics MYGN invests in the development of new innovative testing products and enhances its existing portfolio of testing products. Last year, it launched the new Prequel Prenatal Screen, which delivers critical insights at eight weeks of gestational age as compared to 10 or 12 weeks. Myriad Genetics introduced the Foresight Carrier Screening test with a new Universal Plus Panel featuring an expanded panel of genes and more efficient workflows. Additionally, Myriad Genetics announced early access to the FirstGene — a combined carrier screening and noninvasive prenatal testing assay — and its first AI-enabled Prolaris test to support clinical divisions at the time of biopsy in partnership with OMIC.TEM’s Price Performance & Expensive ValuationIn the past year, Tempus AI shares have surged 83.6%, outperforming the industry’s 38% growth and the S&P 500 composite’s 12.3% improvement.Image Source: Zacks Investment ResearchTEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.50X compared with the industry average of 5.88X.Image Source: Zacks Investment ResearchTEM Stock Estimate TrendEarnings estimates for Tempus AI in 2025 and 2026 are showing a mixed picture.Image Source: Zacks Investment ResearchTEM’s Zacks RankTEM stock currently carries a Zacks Rank #4 (Sell).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity.Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Veracyte, Inc. (VCYT): Free Stock Analysis Report Tempus AI, Inc. (TEM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks